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T4-lysozyme-like foldThe bacterial type VI secretion system (T6SS) is used by donor cells to inject toxic effectors into
receptor cells. The donor cells produce the corresponding immunity proteins to protect themselves
against the effector proteins, thereby preventing their self-intoxication. Recently, the C-terminal
domain of VgrG3 was identiﬁed as a T6SS effector. Information on the molecular mechanism of
VgrG3 and its immunity protein TsaB has been lacking. Here, we determined the crystal structures
of native TsaB and the VgrG3C–TsaB complex. VgrG3C adopts a canonical phage-T4-lysozyme-like
fold. TsaB interacts with VgrG3C through molecular mimicry, and inserts into the VgrG3C pocket.
Structured summary of protein interactions:
VgrG3 and TsaB bind by x-ray crystallography (View interaction)
TsaB and TsaB bind by x-ray crystallography (View interaction)
VgrG3 and TsaB bind by cosedimentation in solution (View interaction)
TsaB and TsaB bind by cosedimentation in solution (1, 2)
TsaB binds to VgrG3 by surface plasmon resonance (1, 2, 3, 4, 5, 6, 7)
VgrG3 and TsaB bind by molecular sieving (View interaction)
TsaB and TsaB bind by molecular sieving (View interaction)
VgrG3 and TsaB bind by x ray scattering (View interaction)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction tube, sheath, and baseplate components [2–6]. Valine–glycineThe type VI secretion system (T6SS), a macromolecular nano-
machine, is involved in the interaction with prokaryotic and
eukaryotic cells [1]. The T6SS organelle is structurally and func-
tionally analogous to contractile phage tails, including the spike,repeat protein G (VgrG), together with hemolysin coregulated pro-
tein (HCP), is secreted and required for the function of the T6SS
machine, and represents the hallmark of T6SS [7]. Gram-negative
bacteria expressing T6SS secrete and deliver toxic effector proteins
into neighboring cells. The T6SS effectors destined for the peri-
plasm degrade the cell wall and cell membrane of the receptor cells
to kill the competitor cells, and the cognate immunity proteins
expressed by the bacterium bind the effectors to prevent self-
intoxication [8–13].
At present, several crystal structures of T6SS effector–immunity
pairs have been determined [11,14–21], but these effectors are
single-domain proteins and considered to transit via the HCP tube
[22]. VgrG3 from Vibrio cholera consists of a bacteriophage-
spike-like N-terminal domain (VgrG3N) acting as an important
Table 1
Data collection and reﬁnement statistics.
SeMet-VgrG3C-TsaB Native-TsaB
Data collection
Space group C2 P212121
Resolution (Å) 50.00–2.40(2.49–2.40)* 50.00–2.79(2.85–2.79)
Rsym or Rmerge 7.3(54.8) 7.7(40.1)
I/rI 27.6(2.9) 25.0(3.0)
Completeness (%) 99.7(98.1) 98.4(99.4)
Redundancy 7.5(6.1) 5.9(5.7)
Reﬁnement
Resolution (Å) 38.16–2.40 44.12–2.79









Bond lengths (Å) 0.009 0.0134
Bond angles () 1.048 1.545
* Values in parentheses are for highest-resolution shell.
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which functions as a peptidoglycan-targeting glycoside hydrolase
[10]. Recent studies have shown that VgrG3C plays a pivotal role
in the ﬁght against competitor cells as a unique T6SS effector
and the type VI secretion antitoxin B protein (TsaB) inhibits
VgrG3C to prevent self-killing [10,12]. However, the structure of
the VgrG-related effector has not yet been reported, which restricts
our understanding of the VgrG and T6SS mechanisms.
Here, we ﬁrst report the crystal structure of the VgrG-related
T6SS effector (VgrG3C). VgrG3C displays a phage-T4-lysozyme-
type fold. Compared with its structural homologs, VgrG3C displays
several unique features, which are associated with its substrate
speciﬁcity. The catalytic residues of VgrG3C are identiﬁed in this
study. The immunity protein TsaB interacts extensively with
VgrG3C, destroying the enzymatic activity of VgrG3C. Unlike other
T6SS immunity proteins, TsaB tends to form oligomer. Importantly,
the oligomerization of TsaB is involved in the inhibition of VgrG3C.
Structural clariﬁcation of the VgrG3C–TsaB complex has revealed
the inhibition mechanism. Our work also extends our understand-
ing of the role of T6SS in interspecies competition.
2. Materials and methods
2.1. Protein expression and puriﬁcation
The DNA encoding the C-terminal domain of VgrG3 (amino
acids 731–1009) was ampliﬁed by PCR from the genomic DNA of
Vibrio cholerae, and ligated into a BamHI/XhoI-digested pET21a(+)
(Novagen) vector. The plasmid of VgrG3C was transformed into
Escherichia coli BL21 (DE3) competent cells for induced expression
with 0.2 mM isopropyl-b-D-1-thiogalactopyranoside (IPTG) at
289 K overnight. The cells were harvested by centrifugation and
resuspended in buffer containing 20 mM Tris pH 8.0, 150 mMNaCl,
2 mM b-Mercaptoethanol, 0.1 mM Phenylmethylsulfonyl Fluoride
(PMSF), 10 lg/ml DNaseI and 1 mM MgCl2. Cells were lysed by
French press and cell debris was removed by centrifugation at
30000g for 50 min. The supernatant was puriﬁed by nickel afﬁn-
ity chromatography. The expression and puriﬁcation of TsaB
(amino acids 27–122) were performed as described previously
[23]. The elution of VgrG3C was concentrated and directly applied
to gel ﬁltration (Superdex™ 200 10/300 GL, GE Healthcare). The
fractions of VgrG3C and TsaB were mixed, and then applied to
gel ﬁltration chromatography. The buffer for gel ﬁltration con-
tained 20 mM Tris pH 8.0, 150 mM NaCl and 1 mM DTT. Pooled
the complex peak and concentrated to 12 mg/ml prior to the
crystallization trial.
2.2. Crystallization and data collection
VgrG3C-TsaB complex was crystallized at 277 K using sitting-
drop vapour-diffusion technique. The crystals of the native
complex were grown by mixing 1 ll of protein solution with 1 ll
reservoir solution consisting of 0.1 mM HEPES pH 7.6 and 16%
(w/v) PEG3350. The crystals were transferred into cryoprotectant
solution (reservoir solution supplemented with ethylene glycol
up to 10% (v/v). The selenomethionine (Se-Met) complex was puri-
ﬁed and crystallized essentially in the same conditions as native
complex. The crystallization of TsaB was performed as described
previously [23]. The X-ray diffraction data were collected at beam-
line 3W1A of Beijing Synchrotron Radiation Facility (BSRF), China.
All datasets were processed with HKL2000 [24].
2.3. Structure determination and reﬁnement
The structure of complex was solved by single-wavelength
anomalous diffraction (SAD) method, the initial phases weredetermined using AutoSol in the PHENIX [25–27] software pack-
age, and density modiﬁcation and automatic model building were
subsequently performed using AutoBuild routine in PHENIX [28].
Further model was manually built by the program COOT [29]. All
the structure reﬁnements were performed by phenix.reﬁne [30]
of the PHENIX package. The ﬁnal model quality was checked with
MolProbity [31] from the GUI of PHENIX. The structure of TsaB was
determined by molecular replacement method with AutoMR [26]
from the GUI of PHENIX using TsaB of Se-Met complex structure
as a search model. Detailed data collection and reﬁnement are pre-
sented in Table 1. All the structure ﬁgures were generated by
PyMol [32].
2.4. Analytical ultracentrifugation (AUC)
For the AUC experiment, proteins were puriﬁed as described
above. AUC was performed using Beckman XL-I analytical ultra-
centrifuge equipped with an An60Ti rotor speed of 60000 rpm at
293 K. All the data were processed by SEDFIT program [33].
2.5. Surface plasmon resonance (SPR)
Binding afﬁnity of effector and immunity was measured by the
technique of surface plasmon resonance (SPR) using a BIAcore
T100 (GE Healthcare) with single-cycle kinetics method. TsaB
(1 lg/ml in 10 mM sodium acetate, pH 4.5) was immobilized on
a CM5 sensor chip (GE Healthcare) up to level of 100RU. VgrG3C
and its mutants were injected over the sensor chip surface in run-
ning buffer (10 mM HEPES pH 8.0, 150 mM NaCl and 0.005 % (v/v)
Tween-20) for 60 s at a ﬂow rate of 30 ll/min. The dissociation
occurred in running buffer for 720 s at the same ﬂow rate and
the sensor chip was regenerated with 10 mM NaOH for 20 s. Data
were analyzed by 1:1 binding model using BIAcore T100 Evalua-
tion software (GE Healthcare).
2.6. Small-angle X-ray scattering (SAXS)
SAXS experiments were performed at beamline 1W2A station in
BSRF using a MARCCD165 detector. The proteins were diluted to
2–4 mg/ml in SAXS buffer (20 mM Tris pH8.0, 150 mM NaCl and
0.2 mM DTT). The experimental one-dimensional data were gener-
ated by PRIMUS [34] software from ATSAS suite. Subsequently, the
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bution function p(r). The theoretical curves derived from CRYSOL
[36] were ﬁtted to the 2-fold complex crystal structure. The ab inito
shape was reconstructed by a chain-like ensemble of dummy res-
idues using GASBOR [37] program. The ﬁnal model was averaged
by DAMAVER [38].
2.7. Cell viability assay
VgrG3 (amino acids 731–1009) and TsaB (amino acids 27–122)
were expressed in the periplasm using pET-22b(+) (Novagen) and
pET-26b(+) (Novagen) vector with a signal peptide, respectively.
The bacteria were incubated in LB medium at 310 K overnight,
and serial 10-fold dilutions were plated onto LB plates carrying
0.03 mM IPTG for the induced expression. The variants were per-
formed with the same protocol.
3. Results
3.1. Structure of the VgrG3C–TsaB heterotetramer complex
The structure of the C-terminal domain of VgrG3 (amino acids
731–1009) complexed with TsaB (amino acids 27–122) was
determined at 2.4 Å resolution. The asymmetric unit contains a
VgrG3C–TsaB heterodimer. However, the molecular mass of the
complex, measured by ﬁltration chromatography and analytical
ultracentrifugation (AUC), indicates that the complex behaves as
a heterotetramer in solution (Figs. 1A and 2). The complex was
further investigated with small-angle X-ray scattering (SAXS).Fig. 1. Heterotetrameric state in solution and crystal structure of VgrG3C–TsaB complex
results show a main peak at 73.2 kDa, corresponding to the 84-kDa heterotetrameric com
experimental scattering curve. Curve2, theoretical scattering curve from the heterotetr
angle. The experimental SAXS curve is consistent with the heterotetramer curve. Right a
VgrG3C–TsaB heterotetramer. (C) Overall structure of the VgrG3C–TsaB heterotetrame
yellow and TsaB in pink and blue.The experimental SAXS data was ﬁtted well to the theoretical curve
derived from the crystallographic heterotetramer (Fig. 1B). Addi-
tionally, the models generated independently according to crystal
packing and SAXS were also consistent, conﬁrming the heterotetr-
amer structure of VgrG3C–TsaB in solution. The heterotetramer
structure can be created by symmetry-related neighboring mole-
cules (Fig. 1C).
3.2. Potential active site in VgrG3C
The overall structure of VgrG3C demonstrates a T4-lysozyme-
like architecture (Fig. 3A). Gel-ﬁltration experiments combined
with AUC conﬁrmed the monomeric nature of VgrG3C (Figs. 3B
and 2). The structure consists of eight a-helices and two 310 heli-
ces, which pack against three-stranded antiparallel b-sheets. The
VgrG3C protein is characterized by two lobes (the C-lobe and the
N-lobe) linked by a backbone helix (a4 helix). The conserved resi-
dues are mainly clustered around the cleft formed by the two lobes
(Fig. 3A, right). A DALI [39] search for structural homologs revealed
several candidates, including the chitosanase from Streptomyces sp.
N174 (N174 chitosanase), the chitosanase from Bacillus circulans
MH-K1 (MH-K1 chitosanase), and the pesticin from Yersinia pestis.
The electrostatic proﬁle of VgrG3C is quite different from those
of its structural homologs, suggesting that the substrates of these
proteins diverge. The active clefts of the chitosanases are highly
acidic, providing suitable sites for the chitosanases to bind the
polycationic chitosans [40–44] (Fig. 4B–D). However, both basic
and acidic patches are distributed around the cleft of VgrG3C
(Fig. 4A).. (A) Analytical ultracentrifugation analysis (AUC) of the VgrG3C–TsaB complex. The
plex. (B) Solution conformation and assembly of the VgrG3C–TsaB complex. Curve1,
amer curve. Curve3, the transformed p(r) curve by extrapolated to zero scattering
bove: superimposition of the SAXS model and the crystallographic structure of the
r. The heterotetrameric structure is generated by crystal packing, with VgrG3C in
Fig. 2. Solution behavior of VgrG3C, TsaB, and the VgrG3C–TsaB complex. Left: Gel-ﬁltration chromatograms of VgrG3C, dimeric TsaB, and VgrG3C–TsaB. Right: Gel-ﬁltration
chromatograms of oligomeric TsaB.
Fig. 3. VgrG3C structure and the potential active site. (A) Left: VgrG3C is divided into the N-lobe (yellow), C-lobe (orange), and the backbone helix (green). The catalytic
residues are shown in stick representations. Right: Conserved residues are mapped onto the VgrG3C surface. Highly conserved residues are shown in maroon and the most
variable residues in cyan. The catalytic residues are labeled. (B) Schematic diagram of AUC. VgrG3C behaves as a monomer in solution. (C) Identiﬁcation of the active site of
VgrG3C with a cell growth assay. The strains containing the periplasmic expression vector were serially diluted and plated onto IPTG agar plates. The VgrG3C wild type and
mutants were present in the periplasm. The cells were killed if the VgrG3C variants retained activity.
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ant amino acids, Glu827 and Asp842, constitute the active dyad
residues of VgrG3C. The variants E827A and D842A failed to sup-
press Escheichia coli growth, suggesting that the catalytic dyad is
essential for the activity of VgrG3C (Fig. 3C). The catalytic mecha-
nisms of glycosyl hydrolases are characterized by the distance
between the catalytic residues [40]. The distance between
Glu827 and Asp842 is above 10 Å, indicating the inverting mecha-
nism. The proposed catalytic details can be inferred from the struc-
tural homologs [40–44]. Glu827, which is positioned at helix a1,
contributes to the protonation process of sugar. Asp842 is believed
to act as a general base, activating a water molecule to attack at the
sugar’s carbon.
In addition, three potential active-site mutations based on
structural comparison (V859A, H910A and K984A) also have been
tested. The result shows that V859A substitution abolished the
activity of VgrG3C, the H910A variant located between helices
a4A and a4B of VgrG3C was found to disrupt its enzymatic activ-
ity. The H910A variant may change the backbone helix orientation,which inﬂuences the shape and volume of the active cleft. But the
mutation of Lys984 had no observable effect on the activity of
VgrG3C (Fig. 3C).
3.3. TsaB tends to form homo-oligomers
Although dimeric TsaB accounts for most of the total protein,
higher oligomeric assemblies also occur in solution. The AUC
and gel-ﬁltration results are fully consistent (Figs. 5A and 2).
The structure of native TsaB was determined at a resolution of
2.8 Å. There are six molecules in an asymmetric unit, which con-
sists of three TsaB dimers (Fig. 5B). TsaB folds into a three-helix
bundle. The six individual molecules are generally well superim-
posed. Apo-TsaB dimer is nearly identical to the TsaB dimer in a
complex (Fig. 5C). It is noteworthy that TsaB molecules also gen-
erate distinct interfaces in the native structure (such as the B–C
interface and D–E interface), suggesting that these interaction
modes may be involved in the formation of higher oligomers
(Fig. 5B).
Fig. 4. Structural comparison with VgrG3C homologs. (A) Above: Cartoon representation, with secondary structure assignments, of VgrG3C. Helices, strands, and 310 helices
are shown in cyan, magenta, and yellow, respectively. The potential active sites are displayed in stick representations. Below: VgrG3C is represented by its electrostatic
surface potential. The electrostatic surface on both sides is dominated by the cationic potential, whereas the central cleft is rich in negatively charged residues. (B–D) Above:
Ribbon diagrams of N174 chitosanase (PDB: 1CHK) (B), MH-K1 chitosanase (PDB: 1QGI) (C), and pesticin (PDB: 4ARQ) (D). The insertions are colored blue. The active loops
and active residues are labeled. Below: The structures are shown in electrostatic surface representations. In these proteins, the cleft is generally acidic.
Fig. 5. Crystal structure of TsaB. (A) AUC proﬁles of oligomeric TsaB fractions (above) and dimeric TsaB fractions (below). The peaks indicate the different oligomeric states of
TsaB. (B) Crystal structure of TsaB. Each monomer is labeled. (C) Superimposition of three native dimers with the dimer in the VgrG3C–TsaB complex. Each dimer is
highlighted in a different color.
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were collected, and then analyzed using AUC (Fig. 5A, below).
Higher oligomeric TsaB was found, indicating that TsaB has a ten-
dency to form oligomers.
3.4. Interaction of VgrG3C with TsaB
TsaB inserts deeply into the VgrG3C cleft, giving rise to an inter-
action interface of 1160 Å2 (Fig. 6A). Tyr826, adjacent to the cat-
alytic residue Glu827 of VgrG3C, donates a hydrogen bond to His35
of TsaB. Notably, the catalytic residue Asp842 of VgrG3C mediates
a number of hydrogen bonds with residues Glu50, Arg54 and Tyr71
of TsaB. Hydrogen bonding also occurs between Asn840 of VgrG3Cand Asn44 of TsaB (Fig. 6B). Similarly, three conserved residues
(Val941, Gln942, and Arg996) located in the C-lobe of VgrG3C are
anchored by their interactions with Gln91 and Arg92 of TsaB.
Hydrogen bonds between Asp992 of VgrG3C and Thr31 of TsaB
and between the backbone oxygen in Leu982 of VgrG3C and the
side-chain nitrogen in Arg92 of TsaB further stabilize the complex
(Fig. 6C).
To characterize the VgrG3C–TsaB interaction in further detail,
we performed afﬁnity and kinetic analyses using SPR (Table 2).
Two residues of VgrG3C (Ser837 and Gln852) that are involved in
its water-mediated interactions with TsaB were also selected for
study. VgrG3C binds to TsaB with high afﬁnity (Kd = 0.98 nM).
The Y826A, D842A, V941A, Q942A, L982A, and R996A variants
Fig. 6. Interaction of VgrG3C with TsaB and the mode of inhibition. (A) Surface representations of the heterodimeric VgrG3C–TsaB complex. The heterodimer is identical to
the other one across a crystallographic axis of twofold symmetry. The heterodimer is only described for clariﬁcation. The coloring scheme is as described in Fig. 1C. (B–C) A
close-up view of the VgrG3C–TsaB complex interface. The residues and water molecules involved in the interaction are shown as sticks and spheres, respectively. (D) Above
panel, growth of E. coli cells in the presence of TsaB and VgrG3C. The cells were rescued by the expression of TsaB. Below panel, growth of E. coli cells in the presence of VgrG3C
mutations. The cells were prepared as serial 10-fold dilutions.
Table 2
Binding afﬁnity parameters for wild-type and mutant VgrG3C binding to TsaB.
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Tyr826 and Asp842 are closely associated with the activity of
VgrG3C. However, substitutions S837A, N840A, Q852A and
D992A did not appear to affect VgrG3C binding, indicating that
the water-bridge contacts mainly complement the direct interac-
tions. Intriguingly, the majority of critical residues linked to the
afﬁnity cluster in the C-lobe, suggesting that the C-lobe is respon-
sible for the binding of VgrG3C to TsaB.
3.5. Mechanism of VgrG3C inhibition by TsaB
The active pocket of VgrG3C is occluded by TsaB, thereby inhib-
iting the activity of VgrG3C (Fig. 6A). Interestingly, several active-
site residues in its structural homologs are equivalent to the
TsaB-binding residues in VgrG3C. Therefore, we proposed that TsaB
partly mimics the substrate of VgrG3C to trap its active site. We
used point mutations and cell assays to conﬁrm this proposition.As anticipated, most mutations of the TsaB-binding residues ren-
dered VgrG3C inactive (Fig. 6D). In contrast, the substitution of
Asp840 and Asp992 did not appear to affect the activity of VgrG3C.
Most notably, the results are consistent with the VgrG3C–TsaB
interaction analysis: only the D840A and D992A variants had little
or no effect on TsaB-binding (Table 2). Together, these results sug-
gest that TsaB inhibits VgrG3C through the molecular mimicry of
its substrate.
The two loops of b1–b2 and a7–a8 in the VgrG3C–TsaB com-
plex structure are ﬁxed, however, a fair degree of ﬂexibility in
the corresponding loops is required for structural homologs activ-
ity [40–44]. Given the interactions between TsaB and these loops,
we infer that these loops undergo structural rearrangement when
native VgrG3C is incorporated into the VgrG3C–TsaB complex.
These active loops in VgrG3C are considered to be mobile in the
absence of immunity proteins.
4. Discussion
Bacteria have evolved various mechanisms to compete against
each other [45]. One such mechanism involves the injection of
effector proteins into the receptor cells via T6SS [8–13]. The C-ter-
minal extension of VgrG3 acts as a lysozyme-like effector. TsaB, the
antagonistic immunity protein, is used to prevent the self-destruc-
tion of the donor cell. In this study, we have performed structural
and biochemical analyses of VgrG3C and TsaB. Overall, VgrG3C dis-
plays a canonical T4-lysozyme-like fold (Fig. 3A). We identiﬁed the
catalytic dyad using cell assay and structural analysis. A long ﬂex-
ible linker (amino acids 731–815) connects VgrG3C to VgrG3N. The
linker could not be mapped because of its ﬂexibility, suggesting the
dynamic nature of VgrG3C [5]. In addition, VgrG3C is also thought
to dissociate from VgrG3N [10], and could be randomly distributed
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strate. This also explains why the bacterial cell wall tends to be
very susceptible to VgrG3 [10,12]. However, there must be effec-
tive strategies to protect the donor and sister cells. The presence
of different oligomeric forms of TsaB may be related to the
dynamic nature of VgrG3C. In other words, dynamic TsaB proteins
can effectively bind to the VgrG3C protein in multiple directions.
The structures identiﬁed here, together with the experimental
investigations undertaken, provide insight into how TsaB inacti-
vates VgrG3C. In our proposed model, TsaB acts as a molecular
mimic of the VgrG3C substrate, inducing an open conformation
of the active loops of VgrG3C. The active loops move outward,
removing the steric constraint. As a result, the active cleft is
blocked by TsaB and the activity of VgrG3C is abolished. To our
knowledge, this unique mode of inhibition is described for the ﬁrst
time here.
In summary, combined with a structural analysis, these
biochemical data offer a framework with which to understand
the mechanism and functions of VgrG3. The emergence of
drug-resistant bacteria has become a critical problem and the
major limitation of bacteriophage therapy is its inability to kill
Gram-negative bacteria [44]. In this context, VgrG3C can poten-
tially be used in the ﬁght against Gram-negative bacteria.
Accession codes
The atomic coordinates and structure factor for SeMet-VgrG3C-
TsaB complex and Native-TsaB have been deposited in the Protein
Data Bank with accession codes 4NSO and 4NSR, respectively.
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